Company intelligence / Profile preview

Sopherion Therapeutics

Princeton, New Jersey, United Statesdhpp.hpfb-dgpsa.ca ↗

Ownership: Private
Employees: ~1
Development stage: Commercial

Overview

Sopherion's lead product Myocet is a liposomal formulation of doxorubicin designed to reduce cardiotoxicity while preserving antitumor efficacy. The company was conducting a global registrational trial of Myocet in combination with trastuzumab and paclitaxel for first-line therapy of patients with metastatic breast cancer[3][4].

Therapeutic areas: Oncology
Modalities: Liposomal formulations
Industry: Biotech

Drug pipeline

1 asset

doxorubicin

Commercial

Indications: Metastatic breast cancer

Partnerships

Exclusive licensing agreement with Zeneus Pharma Ltd. (now Cephalon, Inc.) for the commercialization of Myocet in North America[3][4]

Beyond the preview

Go deeper on Sopherion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sopherion Therapeutics.

Explore the full profile